|Other names||CA4P; CA4PD; fosbretabulin; fosbretabulin disodium|
|Chemical and physical data|
|Molar mass||396.32 g/mol (exact mass : 396.097404) g·mol-1|
|3D model (JSmol)|
Combretastatin A-4 phosphate (fosbretabulin, and its salt fosbretabulin disodium) is a microtubule destabilising drug, a type of vascular-targeting agent, a drug designed to damage the vasculature (blood vessels) of cancer tumours causing central necrosis. It is a derivative of combretastatin.
CA4P is also known as Fosbretabulin Tromethamine.
In July 2007 the pharmaceutical company OXiGENE initiated a 180-patient phase III clinical trial of CA-4-P in combination with carboplatin for the treatment of anaplastic thyroid cancer. There is currently no fully FDA approved treatment for this form of cancer.